Blue Horizon International (BHI), Alpha Blu Skin Care, BHI Therapeutic Sciences, and BHI Rejuve participated in the 27th World Congress on Anti-Aging Medicine & Exhibition in Las Vegas, December 13-15, 2019.
Brian Mehling, M.D. , Founder and Chief Medical Officer of BHI was joined by Klara Doert, President of International Business Development; Katarina Novakova, Director of Relations; Alan DaSilvaPereira, President of BHI Brazil; Fidel Desmar, Clinical Research Coordinator; Ralph Moffetone and John-David Grayson from Industrial Motion Pictures.
BHI Therapeutic Sciences (BHITS) is led by an accomplished scientific and medical team and draws on its relationship with international partners who have successfully treated thousands of patients with stem cell therapy. BHITS was formed to perform research regarding, and to monetize, stem cell technology and associated regenerative medicine. Stem cells are a special type of human cell that can be used to regenerate the human body, in some cases, without drugs or surgery. Regenerative medicine professionals will soon seek to use stem cells to treat various diseases, to extend lifespans and improve the quality of life for certain patients
BHI Rejuve program focuses on anti-aging of the human body, with the help of a complex of vitamins, hormones and stem cell therapy. But the anti-aging part of BHI activities is only one component. Its program is more complex and offers advanced stem cell therapy to patients worldwide.
Blue Horizon International Ambassador Lance “the Party” Palmer is ready to party on New Year’s Eve in Madison Square Garden in NYC
Lance Palmer will be facing Alex Gilpin on December 31, 2019 at the Madison Square Garden in New York City. The fight will air at 7 p.m. EST on ESPN 2.
Palmer—a former All-American wrestler and current MMA champion in the Featherweight Division—credits stem cell treatments from Blue Horizon International (BHI) with a greater feeling of overall health and energy, and more rapid recovery from training.
Palmer received his treatments at the BHI Jamaica, Montego Bay Clinic. “My first stem cell treatment was in 2016,” says Palmer. “I would definitely recommend stem cells to athletes: it helps with the recovery process, preventing injury, and increase in overall energy. I’ve gotten better in the last two years than I have the previous six. I highly recommend Dr. Brian Mehling. He has been most helpful and explained the process step by step. I’ve had a great experience in BHI Jamaica.”
BHI Therapeutics Jamaica provides access to stem cell therapies to patients who may benefit from these treatments. We engage in collaborative relationships with leading scientists and physicians across the globe, utilizing stem cells from either your own body (autologous) or from umbilical cord donors. These donors go through a rigorous testing process to ensure their safety. We do not use embryonic stem cells, nor will we ever—health and safety are our number one priority. We ensure the highest standards of patient safety at our Jamaica Clinic through the collaborative efforts of a Scientific Advisory Board, Ethics Committee, and a staff of US board-certified Physicians. BHI Therapeutics Jamaica provides therapies for neurologic disorders, autoimmune diseases, and orthopedic conditions.
Check us out before the next decade! Check us out today!
www.bluehorizoninternational.com
Come party with The Party as he squares off against Alex Giplin at the Garden tonight! Airs at 7 pm at ESPN 2.
Blue Horizon International CEO Recognized by the International Nurses Association
Doreen Santora, RN, MPH, chief executive officer of Blue Horizon International, will be recognized as a top nurse by the International Nurses Association and will be featured in the publication Worldwide Leaders in Healthcare.
Ms. Santora is receiving this honor for her outstanding acheivements, commitment to education, and demonstrated leadership in her field.
“I am grateful to be recognized by the International Nurses Association,” said Ms. Santora. “It is always nice to be recognized, but when you are honored by your colleagues it is even more special,” she added.
Ms. Santora oversees the operations of Blue Horizon International (BHI) and all of its entities including BHI Therapeutic Sciences, Blue HorizonCharitable Foundation, BHI Rejuve, and Alpha Blu, an innovative skin care line.
She has nearly 30 years of healthcare management experience, Ms. Santora is a registered nurse with a master’s degree in health administration. She is responsible for the day-to-day operations of the BHI and all its subsidies and places a strong emphasis on quality assurance. Ms. Santora focuses on providing outstanding medical care in a high quality, patient friendly environment.
Prior to her position here, she served as senior vice president of operations at one of the busiest and most respected healthcare institutions in the United States, Hackensack University Medical Center.
She was responsible for the growth and development of several nationally and internationally clinical programs that received numerous healthcare awards and distinctions including: outpatient surgery, cardiac surgery, cardiology serves, radiology, sleep medicine, women’s health, executive health, plastic and reconstructive surgery, dermatology, medical spa, pain and palliative care, transfusion-free bloodless medicine, heart failure, and home-based healthcare. Ms. Santora was responsible for more than 1,900 employees and an annual budget of $268 million.
BHI Therapeutic Sciences/ Blue Horizon Stem Cells are the world’s leading provider of adult and children’s stem cell therapies. We have safely and efficiently performed more than 3,000 stem cell research procedures to date. We are the only treatment provider approved and associated with The Wuhan University Department of Medicine, The Biochemistry Institute of Wuhan University. We are fully licensed by the Ministry of Health of the Slovak Republic to offer cord blood, bone marrow and adipose stem cell derived treatments at Malacky Hospital near Bratislava, Slovakia.
The International Nurses Association was founded on the idea that professional achievement is deserving of recognition, exposure and reward. INA is the fastest growing network of nurses from around the globe and takes pride in delivering its members the platform and competitive edge needed to survive in this ever-changing and complex environment. They publish the Nurse Advisor Magazine, Nurse2Nurse Newsletter and others that are packed with the latest advice on stress management, sleep improvement, professional organization and salary negotiating. www.inanurse.com also has blogs, articles and links to helpful resources that can improve quality of life at the clinic or at home. These articles are submitted by nurses, physicians and leading lifestyle experts.
IFBB Pro Champion Anton Antipov Hosts Podcast with Dr. Brian Mehling
On August 2nd, 2019 IFBB Pro Champion and professional fitness model Anton Antipov hosts the podcast Gee Talks, and recently had Dr. Brian Mehling on as a guest to have a long, wide-ranging discussion about the potential of stem cell science.
Antipov has received three stem cell treatments from Dr. Mehling, once in the BHI clinic in Bratislava, Slovakia, and twice in the new Montego Bay, Jamaica clinic, and intends to receive more.
Living Cells
BHI Ambassador and PFL Featherweight Champion Lance Palmer endorses stem cell therapy in BHI Jamaica
Lance Palmer is a featherweight MMA champion who credits stem cell treatments from BHI with a greater feeling of better overall health, more energy, and help with the training recovery process.
Mr. Palmer is a former amateur wrestler and current mixed martial arts fighter. He competes for the Professional Fighters League in the Featherweight division. A four-time NCAA All-American, Mr. Palmer was a member of the Ohio State wrestling team.
Mr. Palmer recently won a fight on July 25, 2019 at the Ocean Casino Resort in Atlantic City, New Jersey via unanimous decision, collecting three regular season points. In the second round Palmer faced Luis Rafael Laurentino at PFL 5. He won the fight via third-round TKO and advanced to the playoffs.
Mr. Palmer has said that his successful treatment at the BHI Jamaica, Montego Bay clinic has helped him become a better fighter. He received his first treatment in 2016 and says it helps with the recovery process, preventing injury, and gave him an overall increase in energy. Mr. Palmer recommends stem cell treatments in general and Dr. Brian Mehling in particular to all other athletes. He describes his experience in the video above.
BHI Therapeutics Jamaica provides access to stem cell therapies to patients who may benefit from these treatments. We engage in collaborative relationships with leading institutions, scientists, and physicians across the globe. We only utilize stem cells from either your own body (autologous) or from umbilical cord donors who have proceeded through a multiple step testing process that ensures stem cell patient safety. We do not use embryonic stem cells, nor will we ever.
BHI Therapeutics Jamaica has US board-certified physicians on staff for your safety. Our Scientific Advisory Board and Ethics Committee oversee the disease-specific protocols to ensure the highest standards of patient safety. BHI Therapeutics Jamaica provides therapies for neurological disorders, autoimmune diseases, and orthopedics conditions.
BHl Rejuve attends The Europa Games Nutrition & Wellness Expo
BHI Rejuve, a hormone optimization program, exhibited at the Europa Games Nutrition & Wellness Expo in Dallas on June 8-9, 2019. Attendees of the conference include individuals who are eager to learn more about improving their quality of life. More than 8,000 wellness enthusiast and professional bodybuilders, competing for their “International Federation of Body Builders (IFBB)” professional cards, attended the two-day event.
Representatives from BHI Rejuve presented information on its hormone optimization program and provided awareness regarding the importance of one’s hormone levels and their effect on one’s quality of life.
The Europa Games Expo has been in existence for more than 10 years with several affiliate conferences held throughout the USA. The conferences attract more than 180,000 people annually. It is one of the very few nutrition and wellness conferences that offers the opportunity to obtain IFBB Pro Cards. In order to become an IFBB pro, a bodybuilder must first earn an IFBB Pro Card. To accomplish this, a bodybuilder l must win a special showcase where he/she is judged on his/her physique.
This year’s conference brought in more than 300 exhibitors, including BHI Rejuve, 24-hour fitness, Bang Energy, Vitamin Shoppe, Orange Theory, US Army, Hello Fresh, Gold’s Gym, and Spartan. Exhibitors had the opportunity to present their companies, goods, and services to bodybuilders, nutrition fanatics and health enthusiasts from across the country.
To check out our video from the event, click the link below.
Dr. Brian Mehling presents in Monaco
Brian Mehling, MD, and Michael Kelly, MD had a successful presentation at the Princess Grace Hospital Monaco in Monte Carlo, France.
Dr. Brian Mehling’s presentation was focused on BHI Therapeutic Sciences (BHITS) stem cell research studies.
It included BHITS stem cell therapy methods, results of Institutional Review Board approved stem cell research studies, resent advances in BHITS stem cell research (Presentation at the American Academy of Orthopedic Surgeons Annual Meeting, New Orleans, Louisiana, 2018 and Presentation at the conference Adult Stem Cells and Regenerative Medicine. The New York Academy of Sciences, NY, 2019) and information on FDA endorsed Investigational New Drug (IND) application entitled Evaluation of the Safety and Efficacy of HPC, Cord Blood in Subjects With Acute Ischemic Stroke.
Dr. Michael Kelly’s presentation was specifically focused on BHITS follow-on IND application entitled “Evaluation of the Safety and Efficacy of Hematopoietic Progenitor Cells, Cord Blood in Subjects with Knee Osteoarthritis Associated Pain”.
It described the study objectives, inclusion and exclusion criteria, safety and efficacy endpoints.
BHI Therapeutic Sciences at World Bank and International Monetary Fund Annual Meetings in DC
Blue Horizon Charitable Foundation was represented at the World Bank and International Monetary Fund Annual Meetings in DC.
This year’s events took place in Washington, D.C. from October 14-20, 2019.
Katarina Novakova, Director of Relations at Blue Horizon Charitable Foundation attended the meetings on behalf of the organization.
The World Bank Group is one of the world’s largest sources of funding and knowledge for developing countries. Its five institutions share a commitment to reducing poverty, increasing shared prosperity, and promoting sustainable development.
Ms. Novakova said: “Participants were discussing the solutions that can trigger inclusive economic growth, why debt transparency is important, what the workable solutions are to tackle the biodiversity crisis, and what are the actions needed to address the education challenge, especially the number of children who can’t read by the age of ten.”
The program of events showcased unique stories that could help inspire others, such as innovations in creating financial and market opportunities for women entrepreneurs, and how investment and innovation in infrastructure have helped deliver sustainable growth and social development for communities and countries.
To boost action and accelerate progress towards tackling development challenges and reducing extreme poverty, delegates from the member countries, observer organizations, civil society, private sector, and media convened at the 2019 Annual Meetings of the World Bank Group and the International Monetary Fund (IMF).
BHI THERAPEUTIC SCIENCES ABSTRACT TO BE PRESENTED AT GERMAN STEM CELL CONFERENCE
BHI Therapeutic Sciences (BHITS) has been invited to present its abstract, “A retrospective chart review study of allogeneic umbilical cord blood mononuclear cell therapy for stroke,” at the German Stem Cell Network;s 7th Annual GSCN Conference being held Sept. 23-25 at the Max Delbruck Center for Molecular Medicine in Berlin.
Marina Manvelyan, PhD., BHITS Clinical Research Scientist said: “We are excited to be part of this gathering to share knowledge with other scientists across the globe. We look forward to learning more about what our colleagues are focusing on in stem cell and regenerative therapies.”
The German Stem Cell Network (GSCN) aims to foster basic and applied stem cell research in Germany. The conference will cover the latest findings in stem cell biology in Germany and includes these scientific sessions:
• Pluripotency and reprograming
• Somatic stem cells and development
• Hematopoietic stem cells
• Stem cells in diseases: cancer stem cells
• Stem cells in regenerative therapies
• Stem cells in disease modeling and drug development
• Computational stem cell biology
“Stem cell therapies are, without a doubt, the future of medicine. I believe
they will become the preferred substitutes for many surgical,
pharmacological, and rehabilitative medical services,”
“The importance of clinical trials and the key direction that it will take will truly
shape the way patients with chronic conditions, disorders, and acute diseases
are treated,” shared Brian Mehling, MD, Chief Medical Officer of BHITS.
BHITS abstract is focused on stroke. Stroke is a leading cause of adult disability worldwide and the second highest cause of death in the world. To date, there are no clinically effective pharmacotherapies that can promote or facilitate cellular functional recovery after an ischemic stroke. Human umbilical cord blood cell therapy is a promising treatment for ischemic stroke. The current retrospective chart review study is aimed to analyze the impact of human umbilical cord blood mononuclear cell therapy on mobility and muscle strength of upper and lower extremities, and neurological function in subjects with ischemic and hemorrhagic stroke.”
Ninety-seven subjects with ischemic and hemorrhagic stroke, treated with human umbilical cord blood mononuclear cells in the Wuhan Hongqiao Brain Hospital Co., Ltd. (Wuhan, Hubei) between March 2009 and March 2012, were included in the retrospective chart review study. Subjects received three administrations of 5 ml human umbilical cord blood mononuclear cells (3×10^8) isolated from human umbilical cord blood of three different donors. Treatment was conducted in three sessions via intravenous and intrathecal administrations. This retrospective chart review study was approved by an Institute of Regenerative and Cellular Medicine Institutional Review Board (IRCM approval number: IRCM-2017-135). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5).
Analysis of post-stroke physical conditions before and two months after the last human umbilical cord blood mononuclear cell therapy session showed improvement of upper and lower extremity mobility and muscle strength, and neurological function (ability to speak, urinary and bowel function). Significant improvement of upper and lower extremity muscle strength was observed in subjects with ischemic and hemorrhagic stroke, treated with human umbilical cord blood mononuclear cells in two or three intrathecal administrations.
BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells. Our stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Our results show our cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions. Multiple studies of umbilical cord blood derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide-range of medical conditions and show promising results. The Food and Drug Administration (FDA) has given us approval to proceed with our Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. For more information, please visit www.bhisciences.com.